Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
mBio. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.
Coronavirus disease 2019 (COVID-19) is the greatest pandemic of our generation, with 16 million people affected and 650,000 deaths worldwide so far. One of the risk factors associated with COVID-19 is secondary bacterial pneumonia. In recent studies on COVID-19 patients, secondary bacterial infections were significantly associated with worse outcomes and death despite antimicrobial therapies. In the past, the intensive use of antibiotics during the severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic led to increases in the prevalence of multidrug-resistant bacteria. The rising number of antibiotic-resistant bacteria and our decreasing capacity to eradicate them not only render us more vulnerable to bacterial infections but also weaken us during viral pandemics. The COVID-19 pandemic reminds us of the great health challenges we are facing, especially regarding antibiotic-resistant bacteria.
2019 年冠状病毒病（COVID-19）是我们这一代人面临的最大的大流行病，目前已有 1600 万人受到感染，全球有 65 万人死亡。与 COVID-19 相关的一个危险因素是继发性细菌性肺炎。在最近对 COVID-19 患者的研究中，尽管进行了抗菌治疗，但继发性细菌感染与更差的结局和死亡显著相关。过去，在严重急性呼吸综合征冠状病毒（SARS-CoV）大流行期间大量使用抗生素导致了多重耐药菌的流行率增加。抗生素耐药菌的数量不断增加，而我们消除它们的能力却在下降，这不仅使我们更容易受到细菌感染的影响，而且在病毒性大流行期间也使我们变得脆弱。COVID-19 大流行提醒我们，我们正面临着巨大的健康挑战，尤其是在抗生素耐药菌方面。
